COMPOSITIONS AND METHODS FOR TREATING HCV
This disclosure is directed to pharmaceutical compositions that comprise two or more therapeutic agents that, inter alia, are useful for inhibiting hepatitis C virus (HCV) and methods for inhibiting HCV by co-administering two or more anti-HCV therapeutic agents.
1 . A combination or pharmaceutical composition comprising an amount of therapeutic agent A and an amount of therapeutic agent B, wherein therapeutic agent A is compound A or a salt thereof:
and wherein therapeutic agent B is compound B or a salt thereof:
2 . The combination or composition of claim 1 , wherein the amount of therapeutic agent A is about 25 mg.
3 . The combination or composition of claim 1 , wherein therapeutic agent B is a sodium salt of compound B.
4 . The combination or composition of claim 1 , wherein the amount of therapeutic agent B is from about 400 to about 800 mg.
5 . The combination or composition of claim 1 , wherein the amount of therapeutic agent A and the amount of therapeutic agent B together constitute a therapeutically effective amount.
6 . The combination or composition of claim 1 , wherein the composition further comprises one or more additional therapeutic agents.
7 . The combination or composition of claim 6 , wherein the additional therapeutic agent is independently selected from the group consisting of ribavirin, taribavirin, and HCV inhibitor.
8 . The combination or composition of claim 6 , wherein the one or more additional therapeutic agents include an HCV protease inhibitor.
9 . The combination or composition of claim 8 , wherein the one or more additional therapeutic agents include a cytochrome P-450 inhibitor.
10 . The combination or composition of claim 9 , wherein the cytochrome P-450 inhibitor is ritonavir.
11 . The combination or composition of claim 6 , wherein the amount of therapeutic agent A, the amount of therapeutic agent B ant the amount of the additional therapeutic agent together constitute a therapeutically effective amount.
12 . A pharmaceutical composition comprising an amount of therapeutic agent A and an amount of therapeutic agent B,
wherein therapeutic agent A is compound A or a salt thereof:
wherein therapeutic agent B is compound B or a salt thereof:
and
wherein the ratio of therapeutic agent A to therapeutic agent B is about 1:20 to about 1:2000.
13 . The pharmaceutical composition of claim 12 , wherein the amount of therapeutic agent B is about 200 mg.
14 . The pharmaceutical composition of claim 12 , wherein the amount of therapeutic agent A is from about 5 mg to about 200 mg.
15 . The pharmaceutical composition of claim 12 , wherein the composition further comprises one or more additional therapeutic agents
16 . The pharmaceutical composition of claim 15 , wherein the one or more additional therapeutic agents include an HCV protease inhibitor.
17 . The pharmaceutical composition of claim 16 , wherein the one or more additional therapeutic agents include a cytochrome P-450 inhibitor.
18 . The pharmaceutical composition of claim 12 , further comprising an HCV protease inhibitor and a cytochrome P-450 inhibitor.
19 . The pharmaceutical composition of claim 18 , wherein the cytochrome P-450 inhibitor is ritonavir.
20 . The pharmaceutical composition of claim 12 , wherein therapeutic agent B is a sodium salt of compound B.